MNPR vs MSFT: Which Stock is Better?
Side-by-side comparison of Monopar Therapeutics and Microsoft Corp in 2026
MNPR
Monopar Therapeutics
$70.32
MSFT
Microsoft Corp
$454.79
Key Metrics Comparison
| Metric | MNPR | MSFT | Winner |
|---|---|---|---|
| Market Cap | $469.92M | $3.38T | MSFT |
| P/E Ratio | N/A | 36.30 | MSFT |
| EPS (TTM) | $N/A | $13.70 | MSFT |
| Revenue Growth | 0.0% | 14.9% | MSFT |
| Gross Margin | 0.0% | 68.8% | MSFT |
Analyze MNPR
Full quant analysis
Analyze MSFT
Full quant analysis
Analyze Each Stock
Frequently Asked Questions
Is MNPR or MSFT a better investment?
Comparing MNPR and MSFT: Monopar Therapeutics has a market cap of $469.92M while Microsoft Corp has $3.38T. Both companies have their strengths - use our detailed metrics comparison to make an informed decision.
What is the difference between MNPR and MSFT?
MNPR (Monopar Therapeutics) and MSFT (Microsoft Corp) differ in valuation, growth rates, and profitability metrics. Our comparison shows which company leads in each category.
Which stock has better value: MNPR or MSFT?
Based on P/E ratios, compare detailed valuation metrics on our dashboard.
Which is growing faster: MNPR or MSFT?
MSFT has higher revenue growth at 14.9% vs 0.0% for MNPR.
Which company is more profitable: MNPR or MSFT?
Microsoft Corp (MSFT) has higher gross margins at 68.8% compared to 0.0% for MNPR.
Which is the larger company: MNPR or MSFT?
Microsoft Corp (MSFT) is larger with a market cap of $3.38T compared to $469.92M for MNPR.
Should I buy MNPR or MSFT in 2026?
Both MNPR and MSFT have investment merit. MNPR trades at $70.32 while MSFT trades at $454.79. Consider your investment goals, risk tolerance, and portfolio diversification before deciding. Our AI analysis tools can provide personalized insights.
What are the key differences between MNPR and MSFT stock?
Key differences: Market Cap ($469.92M vs $3.38T), P/E Ratio (N/A vs 36.3x), Revenue Growth (0.0% vs 14.9%), Gross Margin (0.0% vs 68.8%).